100 related articles for article (PubMed ID: 18824848)
1. Loss of bladder sensation following taxane therapy.
Shah-Khan F; Shah P
Chemotherapy; 2008; 54(6):425-6. PubMed ID: 18824848
[No Abstract] [Full Text] [Related]
2. Taxane effect in a bladder washing.
Dustin SM; Jeffus SK; Stelow EB
Diagn Cytopathol; 2015 Jan; 43(1):32-3. PubMed ID: 24644138
[No Abstract] [Full Text] [Related]
3. [Efficacy of trastuzumab alone therapy was compared to trastuzumab plus taxane therapy in patients of advanced and metastatic breast cancers].
Sakurai K; Enomoto K; Kitajima A; Tani M; Amano S
Gan To Kagaku Ryoho; 2007 Nov; 34(12):1911-3. PubMed ID: 18219850
[TBL] [Abstract][Full Text] [Related]
4. GM1 for taxane-induced neuropathy in breast cancer.
Das M
Lancet Oncol; 2019 Jul; 20(7):e348. PubMed ID: 31130320
[No Abstract] [Full Text] [Related]
5. Survival following the documentation of platinum and taxane resistance in ovarian cancer.
Büyükçelik A; Yalçin B; Utkan G; Doruk H
Gynecol Oncol; 2004 Dec; 95(3):774-5; author reply 775-6. PubMed ID: 15582006
[No Abstract] [Full Text] [Related]
6. Drug evaluation: Bay-59-8862.
Eckstein JW
IDrugs; 2004 Jun; 7(6):575-81. PubMed ID: 15197663
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Modi S; DiGiovanna MP; Lu Z; Moskowitz C; Panageas KS; Van Poznak C; Hudis CA; Norton L; Tan L; Stern DF; Carter D; Seidman AD
Cancer Invest; 2005; 23(6):483-7. PubMed ID: 16203655
[TBL] [Abstract][Full Text] [Related]
8. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy.
Wampler MA; Topp KS; Miaskowski C; Byl NN; Rugo HS; Hamel K
Arch Phys Med Rehabil; 2007 Aug; 88(8):1002-8. PubMed ID: 17678662
[TBL] [Abstract][Full Text] [Related]
9. Estramustine potentiates taxane in prostate and refractory breast cancers.
Hamilton A; Muggia F
Oncology (Williston Park); 2001 May; 15(5 Suppl 7):40-3. PubMed ID: 11396364
[TBL] [Abstract][Full Text] [Related]
10. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Estévez LG; Gradishar WJ
Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
[TBL] [Abstract][Full Text] [Related]
11. Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.
Ali SM; Miller VA; Ross JS; Pal SK
Eur Urol; 2015 Jun; 67(6):1195-1196. PubMed ID: 25630452
[No Abstract] [Full Text] [Related]
12. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Keller AM; Mennel RG; Georgoulias VA; Nabholtz JM; Erazo A; Lluch A; Vogel CL; Kaufmann M; von Minckwitz G; Henderson IC; Mellars L; Alland L; Tendler C
J Clin Oncol; 2004 Oct; 22(19):3893-901. PubMed ID: 15459210
[TBL] [Abstract][Full Text] [Related]
13. Taxane benefit in breast cancer--a role for grade and chromosomal stability.
A'Hern RP; Jamal-Hanjani M; Szász AM; Johnston SR; Reis-Filho JS; Roylance R; Swanton C
Nat Rev Clin Oncol; 2013 Jun; 10(6):357-64. PubMed ID: 23648828
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer (metastatic).
Stebbing J; Glassman R
Clin Evid; 2005 Jun; (13):2197-225. PubMed ID: 16135325
[No Abstract] [Full Text] [Related]
15. [Neoadjuvant chemotherapy for breast-conservative surgery].
Kusama M; Kaise H; Koyanagi Y
Nihon Rinsho; 2000 Apr; 58 Suppl():215-22. PubMed ID: 11025998
[No Abstract] [Full Text] [Related]
16. New natural taxane diterpenoids from Taxus species since 1999.
Shi QW; Kiyota H
Chem Biodivers; 2005 Dec; 2(12):1597-623. PubMed ID: 17191958
[No Abstract] [Full Text] [Related]
17. Ixabepilone: a new microtubule-targeting agent for breast cancer.
Higa GM; Abraham J
Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
[TBL] [Abstract][Full Text] [Related]
18. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
[TBL] [Abstract][Full Text] [Related]
20. [Standard chemotherapy for metastatic breast cancer].
Tashiro H
Nihon Rinsho; 2000 Apr; 58 Suppl():246-53. PubMed ID: 11026002
[No Abstract] [Full Text] [Related]
[Next] [New Search]
